Schools get federal funding to stock naloxone and train staff for overdose emergencies

What it does

This bill authorizes federal grants to schools to stock naloxone (an opioid overdose reversal drug) and train school staff to administer it in emergencies. Schools receiving grants must designate trained personnel, maintain accessible naloxone supplies, ensure trained staff are present during operating hours, and operate under state civil liability protections for staff who administer the drug.

Why we flagged it

The bill's core mechanism is a federal grant program to equip schools with naloxone and trained personnel to respond to opioid overdoses. It is a straightforward public health intervention, not a regulatory carve-out or industry subsidy.

What the text implies

• Naloxone manufacturers (Amphastar, Emergent BioSolutions, Pfizer, others) may see increased demand if schools purchase supplies, though the bill does not mandate procurement from specific vendors or guarantee purchase volumes.
• Schools must establish civil liability protections for staff before receiving grants; states lacking adequate Good Samaritan laws may need to pass new legislation, creating a compliance burden on state legislatures.
• The bill does not specify funding levels or appropriations; actual impact depends on congressional appropriations decisions, which are not yet determined.
• Grants are discretionary (Secretary 'may' award, not 'shall'), giving the administering agency significant discretion over which schools and districts receive funding.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to a life-saving emergency treatment in schools, where opioid overdoses among students are an increasing public health threat. It imposes no restrictions on citizens' rights or remedies; instead, it funds a protective measure and requires schools to meet safety and training standards before receiving grants.

Who stands to gain

• naloxone manufacturers (Amphastar, Emergent BioSolutions, Pfizer, others)
• pharmaceutical distributors
• school-based health center operators

Named in the bill

Department of Health and Human Services (HHS), Public Health Service Act, Amphastar Pharmaceuticals, Emergent BioSolutions, Pfizer, Bristol Myers Squibb, Johnson & Johnson, DaVita (DVA), State attorneys general, Elementary and secondary schools

Where it stands

6 cosponsors: 5 Democrats, 1 Republicans.

• Jan 7, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 7, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.